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The last decades of Nobel prize-honored research have unequivocally proven a key role
of dendritic cells (DCs) at controlling both T cell immunity and tolerance. A tight balance
between these opposing DC functions ensures immune homeostasis and host integrity.
Its perturbation could explain pathological conditions such as the attack of self tissues,
chronic infections, and tumor immune evasion. While recent insights into the complex DC
network help to understand the contribution of individual DC subsets to immunity, the
tolerogenic functions of DCs only begin to emerge. As these consist of many different
layers, the definition of a “tolerogenic DC” is subjected to variation. Moreover, the
implication of DCs and DC subsets in the suppression of autoimmunity are incompletely
resolved. In this review, we point out conceptual controversies and dissect the various
layers of DC-mediated T cell tolerance. These layers include central tolerance, Foxp3+
regulatory T cells (Tregs), anergy/deletion and negative feedback regulation. The mode and
kinetics of antigen presentation is highlighted as an additional factor shaping tolerance.
Special emphasis is given to the interaction between layers of tolerance as well as their
differential regulation during inflammation. Furthermore, potential technical caveats of DC
depletion models are considered. Finally, we summarize our current understanding of
DC-mediated tolerance and its role for the suppression of autoimmunity. Understanding
the mechanisms of DC-mediated tolerance and their complex interplay is fundamental
for the development of selective therapeutic strategies, e.g., for the modulation of
autoimmune responses or for the immunotherapy of cancer.
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INTRODUCTION
Tolerance can be defined by the complete absence or partial
inhibition of a potentially harmful adaptive immune response.
Immunological tolerance operates continuously in order to pro-
tect mammals not only from the deleterious attack of self tissues,
but also from the rejection of semi-allogeneic offspring and
from uncontrolled immune responses against foreign antigens
(Goodnow et al., 2005; Trowsdale and Betz, 2006; Erlebacher,
2010; Berod et al., 2012). Therefore, although tolerance is a
prerequisite for the existence of mammal species, excessive toler-
ance can become similarly life threatening, e.g., by circumventing
cancer immunosurveillance, or by dampening pathogen-specific
immunity and thereby causing lethal or chronic infections (Zou,
2006; Belkaid, 2007; Berod et al., 2012). Thus, a fine-tuned bal-
ance between tolerance and immunity allows for the specific
attack and clearance of dangerous pathogens and transformed
cells, whereas harmless self tissues, commensal microorganisms,
food- and environmental antigens remain ignored. The risk of
tolerance dysregulation and autoimmunity may, however, be the
evolutionary price of having a highly specialized immune sys-
tem. Indeed, a recent study identified pathogens as the major
driving force for the local genetic adaptation of humans, sug-
gesting co-evolution between microbes and the human immune
system (Fumagalli et al., 2011). Strikingly, gene loci that confer
susceptibility for autoimmune diseases including type I diabetes,
colitis, and rheumatoid arthritis, represent prominent targets for
this pathogen-driven selection (Fumagalli et al., 2011). Thus,
although such alleles may have evolved for better pathogen con-
trol, they likely also contribute to autoimmunity, exemplifying
that tolerance and immunity are two sides of a double-edged
sword.
Dendritic cells (DCs) populate virtually all tissues and serve
as sentinels equipped to detect potential threats. Rapidly, they
induce responses in order to protect the host. These include
innate immune cell activation and recruitment, inflammation,
orchestration of adaptive immunity, and immunological mem-
ory. Thus, DCs are “natural adjuvants” bridging innate and
adaptive immunity and have clinically been exploited for almost
a century to prevent life-threatening infections by vaccination.
Additionally, by integrating environmental signals, DCs criti-
cally balance tolerance and immunity (Banchereau and Steinman,
1998; Hawiger et al., 2001; Probst et al., 2005).
DC-mediated tolerance can be segregated into at least four lay-
ers: central tolerance, Foxp3+ regulatory T cells (Tregs), anergy/
deletion and feedback regulation. Additionally, interactions
between these layers need to be considered. Although insufficient
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insights into the regulation of individual layers is still a limiting
factor in resolving the complexity of DC-mediated tolerance, cen-
tral aims of this review are (1) to dissect the multiple layers of
DC-mediated tolerance according to current knowledge; (2) to
discuss whether tolerancemechanisms are inherent to or acquired
by particular DC subsets and how individual layers of tolerance
are regulated by inflammation; and (3) to examine the role of DCs
for the suppression of autoimmunity.
DCs AND FOXP3+ TREGS: GUARDIANS OF T CELL IMMUNITY
DCs are heterogeneous with respect to subset composition,
localization and function. The DC network across the tissues
of different mammal species was recently classified into five
conserved subsets. These subsets share common developmental
requirements, gene expression patterns, and/or functional
specializations and comprise: two types of conventional DCs
(CD8α-like cDCs and CD11b-like cDCs), plasmacytoid DCs
(pDCs), monocyte-derived DCs (Mo-DCs), and Langerhans
cells (LCs) (reviewed in Geissmann et al., 2010; Guilliams
et al., 2010a,b; Bar-on et al., 2011b; Belz and Nutt, 2012).
Although this simplified model helps to understand parallels
between mice and men, markers to identify DC subsets differ
substantially between species. In mice, CD8α-like cDCs comprise
lymphoid organ-resident CD8α+CD103+/−CD11b−DEC-
205+DNGR-1+ cDCs and non-lymphoid tissue migratory
CD8α−CD103+CD11b−DEC-205+DNGR-1− cDCs (Sancho
et al., 2008; Ginhoux et al., 2009; Del Rio et al., 2010; Edelson
et al., 2010). Both subsets will be summarized as CD8α/CD103+
cDCs in the following. CD11b-like cDCs (later called CD11b+
cDCs) include lymphoid organ-resident and non-lymphoid
tissue migratory CD11b+ cDCs, both being heterogeneous and
comprising further subgroups (Ginhoux et al., 2009; Guilliams
et al., 2010b; Henri et al., 2010). While CD11b+ cDCs are more
specialized in innate responses and CD4+ T cell immunity,
CD8α/CD103+ cDCs are efficient at cross-presenting exogenous
antigens (Guilliams et al., 2010b). The intestinal lamina propria is
the only known site populated by CD11b+ Mo-DCs in the steady
state and it further contains a CD103+CD11b+ migratory cDC
subset with unique developmental and functional characteristics
(Jaensson et al., 2008; Bogunovic et al., 2009; Ginhoux et al.,
2009; Schulz et al., 2009; Helft et al., 2010).
One critical component of DC-mediated tolerance is the inter-
action of DCs with immunosuppressive CD4+ Tregs (Tarbell
et al., 2004). Foxp3 was identified as a master regulator of CD4+
Treg function through transcriptional control of around 1100 tar-
get genes (Fontenot et al., 2003; Hori et al., 2003; Khattri et al.,
2003; Apostolou et al., 2008). However, Foxp3 itself is dispensable
for Treg lineage commitment and thus for part of the Treg-specific
transcriptome (Lin et al., 2007; Lahl et al., 2009). Foxp3 is highly
restricted to CD4+TCRαβ+ Tregs in mice with the exception
of its transient expression by a minor population of non-Tregs
(Komatsu and Hori, 2007; Liston et al., 2007; Sakaguchi et al.,
2008; Kim et al., 2009; Wolf et al., 2010; Mayer et al., 2012; Miyao
et al., 2012). Moreover, Foxp3 is expressed by few CD8+ T cells
that were recently shown to expand after allogeneic bone marrow
transplantation (Mayer et al., 2011; Robb et al., 2012). Of note,
in humans additional markers like CD45RA and CD45RO help
to discriminate Foxp3+ Tregs from activated T cells (Sakaguchi
et al., 2010).
Foxp3+ Tregs comprise two major subsets, natural and
induced Tregs. Both subsets are devoted to immune suppression
and most likely act in a complementary fashion by extending T
cell receptor diversity (Haribhai et al., 2011). Natural Foxp3+
Tregs develop as distinct T cell lineage in the thymus in a DC-
independent fashion (Ohnmacht et al., 2009). In contrast, DCs
critically control induced Foxp3+ Treg generation from Foxp3−
T cells in the periphery. Additionally, DCs tailor the periph-
eral homeostasis of both natural and induced Foxp3+ Tregs (see
“DCs and Foxp3+ Tregs”). Requirements for natural and induced
Foxp3+ Treg development, as well as their immunosuppressive
activities, have previously been reviewed (Curotto De Lafaille and
Lafaille, 2009; Huehn et al., 2009; Josefowicz and Rudensky, 2009;
Sakaguchi et al., 2009; Ohkura and Sakaguchi, 2010; Berod et al.,
2012; Hsieh et al., 2012). However, these issues are far from being
completely solved.
TOLEROGENIC DCs
The term “tolerogenic” is increasingly being used to character-
ize certain DC functions or DC subsets. However, its defini-
tion can be quite intuitive. For example, tolerogenicity has been
attributed to DCs solely based on the expression of one or more
immunosuppressive molecules. Conversely, reduced expression
of immunostimulatory molecules has similarly been regarded
as a tolerogenic property. Other definitions include the capac-
ity of a DC to generate Tregs or its inability to generate a T cell
response. Whether these T cell responses are measured in vitro
or in vivo is up to the scientist’s definition. Moreover, the use
of in vitro generated or ex vivo isolated DCs adds an additional
level of complexity. Finally, various protocols have been devel-
oped to generate “tolerogenic” DCs by pharmacologic treatment
(reviewed in Maldonado and Von Andrian, 2010). These exam-
ples illustrate that the term “tolerogenic DC” is vaguely defined
and requires refinement.
Figure 1 outlines different models of DC-mediated tolerance.
Classically, DCs are believed to retain an immature/semi-mature
steady state in order to primarily induce tolerance (Steinman
et al., 2003). The triggering of diverse pattern recognition recep-
tors, cytokine receptors or co-stimulatory receptors (e.g., through
infections) lead to DC maturation (Figure 1A). Maturation is
characterized by increased densities of MHC: peptide complexes
and co-stimulatory molecules like CD80/CD86 on the surface
of a DC, as well as the release of inflammatory cytokines and
chemokines (Steinman et al., 2003). Matured DCs are consid-
ered to be potent stimulators of immunity (Figure 1A). However,
as the mere expression of known co-stimulatory molecules like
CD80/CD86 is not indicative of an immunogenic function, this
classical view has been refined (Reis E Sousa, 2006). In this new
model, maturation is rather seen functionally and results in the
generation of immunogenic DCs, e.g., involving the licensing
of DCs by CD4+ T cell help (Reis E Sousa, 2006). Thus, DC-
mediated tolerance can be classically described by a situational
fate decision where the DC either achieves functional matura-
tion and becomes immunogenic, or fails to mature and promotes
tolerance (Figure 1A).
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FIGURE 1 | Classical models of DC-mediated tolerance. It is a long
standing controversy how DCs mediate immunological tolerance. (A) One
classical view is that the maturation status of DCs acts as a switch,
determining the decision for either tolerance in the steady state
(immature/semimature DCs) or for immunity upon inflammation (mature
DCs). (B) The subsequent discovery of immunosuppressive regulatory
T cells that can be activated by both immature and mature DCs, raised the
possibility for functional dichotomy. This means that a DC is capable of
potentially executing both tolerogenic and immunogenic immune
responses as parallel events. (C) Certain DC subsets were proposed to be
inherently more potent in tolerance induction compared to other DC
subsets. In this model, a division of labor between DC subsets regulates
tolerance versus immunity.
A key question remains how matured DCs can distinguish
between pathogen-specific T cells and T cells autoreactive to ubiq-
uitous self antigens. In fact, the maintenance of self tolerance may
become even more important during inflammatory conditions
than during the steady state in order to prevent autoimmu-
nity. Taking this into consideration, one can postulate that even
matured immunogenic DCs continue to promote tolerance. In
this model, DCs possess a functional dichotomy by promoting
tolerance and immunity as parallel events (Figure 1B), although
it fails to explain the abrogation of tolerogenic DC functions
upon inflammation, as observed in certain experimental settings
(Hawiger et al., 2001; Laffont et al., 2010).
An alternative model is the preferential induction of tolerance
by specialized DC subsets (Del Rio et al., 2010; Lutz et al., 2010;
Matta et al., 2010; Scott et al., 2011). Here, a division of labor
between DC subsets might regulate tolerance versus immunity
(Figure 1C). Tolerogenicity may be acquired either inherently or
by environmental conditioning of certain DC subsets. However,
if certain DC subsets are specialized at inducing tolerance in the
steady state, it is still not clear why the in vivo elimination of these
DC subsets so far failed to elicit autoimmunity (Kaplan et al.,
2005; Hildner et al., 2008; Swiecki et al., 2010; Takagi et al., 2011).
Therefore, although these different models help to describe cer-
tain findings, they fail to fully describe DC-mediated tolerance.
Instead, tolerance might be better understood as various interact-
ing and differentially regulated layers that will be dissected in the
following paragraphs and in Figure 2.
LAYERS OF DC-MEDIATED TOLERANCE
DCs AND CENTRAL TOLERANCE
The thymus produces T cells with random specificities. This cre-
ates the problem that potentially harmful autoreactive T cells are
readily generated. For this reason, the thymic elimination of such
autoreactive T cells (so called negative selection) represents an
essential component of tolerance (Figure 2A). Negative selection
is thought to involve DCs (Kyewski et al., 1986; Brocker et al.,
1997; Volkmann et al., 1997). The majority of thymic DCs local-
ize to the medulla or cortico-medullary junction and comprise
CD8α/CD103+ cDCs (∼50% of total DCs), pDCs (∼35%) and
CD11b+ cDCs (∼15%) (Wu and Shortman, 2005). Consistent
with DC localization, the thymic medulla is the primary site for
negative selection. However, negative selection can also occur at
a very early developmental stage in the cortex, with involvement
of both cortical thymic epithelial cells (cTECs) and rare corti-
cal DCs (McCaughtry et al., 2008). Most CD8α/CD103+cDCs
seem to derive locally from thymic T cell precursors, whereas
pDCs and CD11b+ cDCs likely originate from the circulation,
thereby importing peripheral antigens for negative selection (Wu
and Shortman, 2005; Bonasio et al., 2006; Li et al., 2009; Hadeiba
et al., 2012).
Additionally, non-hematopoietic medullary epithelial cells
(mTECs) express and directly present tissue-specific antigens
under the control of AIRE (Anderson et al., 2002; Kyewski and
Klein, 2006). On the one hand, it was elegantly demonstrated via
independent approaches that this DC-independent type of anti-
gen presentation can be sufficient to mediate the negative selec-
tion of T cells specific for particular model antigens (Luckashenak
et al., 2008; Hinterberger et al., 2010). On the other hand, this may
largely depend on the type, localization and concentration of the
respective antigen. Indeed, mTEC-mediated negative selection
was proposed to be incomplete and to require hematopoietic anti-
gen presenting cells such as medullary DCs which cross-present
mTEC-derived antigens (Barclay and Mayrhofer, 1981; Gallegos
and Bevan, 2004; Kurobe et al., 2006). This may explain the
thymic predominance of the CD8α/CD103+ cDC subset which is
highly efficient at cross-presentation (Dresch et al., 2011). Thus,
DCs likely contribute to central tolerance [(Klein et al., 2011);
Figure 2A], although the role of individual DC subsets remain to
be established.
DCs AND PERIPHERAL TOLERANCE
Several mechanisms of peripheral tolerance operate after T cells
have completed their thymic development and have entered the
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FIGURE 2 | Layers of DC-mediated tolerance. DCs promote tolerance via
multiple layers, thereby rendering the term “tolerogenic DC” highly
indefinite. (A) DCs are implicated in the negative selection of self-reactive T
cells and thus in central tolerance, although this is still a subject of intense
research. (B) DCs are critically involved in the de novo generation,
homeostasis and activation of Foxp3+ Tregs which play a non-redundant role
in the suppression of lethal autoimmunity. Foxp3+ Treg activation by
DC-associated MHC-class-II: peptide complexes and CD80/CD86 is crucial to
activate the immunosuppressive properties of Foxp3+ Tregs and to induce
their expansion. Additionally, IL-2 and TGF-β, which can be produced by DCs,
are critically involved in the maintenance of Treg function and proliferation.
DC-derived TGF-β can also act on Foxp3− T cells to convert them into Foxp3+
Tregs. This process is enhanced by retinoic acid (RA) which is generated in
DCs from retinaldehyde by the enzyme Raldh2. PD-1 ligands (PD-L1 and
PD-L2) were also implied in Foxp3+ Treg induction. (C) Recessive peripheral
tolerance is established in a T cell-intrinsic manner following instructive
encounters with DCs. Antigenic activation of Foxp3− T cells can result in their
functional inactivation (clonal anergy). This partly depends on the triggering of
PD-1 on T cells via its ligands PD-L1 and PD-L2. Similarly, signaling via
CTLA-4 can induce clonal anergy (not depicted). Another outcome of
recessive tolerance can be clonal T cell deletion which depends on
interactions via TNF/TNFR2, FasL/Fas or induction of the pro-apoptotic factor
Bim. (D) Multiple mechanisms can result in the feedback inhibition of DCs.
Foxp3+ Tregs bind the co-stimulatory molecules CD80/CD86 on DCs via
CTLA-4. This interaction leads to the production of
indolamine-2,3-dioxygenase (IDO) and in the suppression of DC maturation
(not depicted). IDO causes the apoptosis of conventional T cells and activates
Foxp3+ Tregs. TGF-β produced and activated by DCs can directly inhibit DC
functions. Additionally, signaling via TLRs (e.g., TLR2), DC-SIGN and the
Wnt/β-catenin pathway can result in the production of IL-10 by DCs. IL-10
potently inhibits DC maturation/function and induces IL-10-producing TR1
cells, thereby creating a regulatory feedback loop.
periphery. One is dominant, cell-extrinsic and exerted by Foxp3+
Tregs (Figure 2B). In contrast, so-called recessive peripheral tol-
erance is characterized by a T cell-intrinsic mode of action
(Sakaguchi et al., 2008). Examples for recessive tolerance are
clonal deletion that results from activation-induced cell death,
and clonal anergy which represents a state of functional unre-
sponsiveness (Figure 2C). Finally, negative feedback regulation
contributes to peripheral tolerance and will also be considered
(Figure 2D).
DCs and Foxp3+ Tregs
Interactions between Foxp3+ Tregs and DCs comprise the main-
tenance/activation of Foxp3+ Tregs and their de novo differentia-
tion (Figure 2B). In this section, both aspects will be pointed out.
Additionally, putative differential regulation upon inflammation
and the involvement of DC subsets are discussed.
Foxp3+ Treg maintenance/activation. DCs frequently form
contacts with Foxp3+ Tregs which in vitro depend on both
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antigen and LFA-1 (Tarbell et al., 2004; Sakaguchi et al., 2009).
Thereby, Foxp3+ Tregs compete with conventional T cells for
forming interactions with DCs (Figure 2B). Consequently, the
clustering of Foxp3+ Tregs around DCs physically inhibits the
activation of conventional T cells. Furthermore, Foxp3+ Tregs
become activated in response to much lower antigen con-
centrations than conventional T cells even if immature DCs
present the antigens (Takahashi et al., 1998; Tarbell et al., 2004;
Sakaguchi et al., 2008). Once activated, Foxp3+ Tregs prolif-
erate (Figure 2B), enrich at sites of specific antigen encounter,
become highly suppressive and may infiltrate inflamed tissues
in order to locally confer transient or long-term immune reg-
ulation (Yamazaki et al., 2003; Samy et al., 2005; Lahl et al.,
2009; Wheeler et al., 2009; Rosenblum et al., 2011). Accordingly,
the loss of MHC-class-II expression on DCs results in decreased
Treg proliferation and markedly reduced numbers of Foxp3+
Tregs (Darrasse-Jeze et al., 2009). Besides antigenic stimulation,
Foxp3+ Treg homeostasis involves CD28-derived co-stimulatory
signals (Figure 2B). In non-obese diabetic (NOD) mice, CD28-
or CD80/CD86 deficiency causes drastically reduced numbers
of Tregs which results in the onset of autoimmune diabetes
(Salomon et al., 2000). Additionally, IL-2- and TGF-β-induced
signals were shown to maintain Foxp3 expression, Treg suppres-
sive function, and/or survival [(Marie et al., 2005; Setoguchi
et al., 2005; Sakaguchi et al., 2008); Figure 2B]. Treg home-
ostasis could involve IL-2 trans-presentation by CD25-expressing
DCs [(Wuest et al., 2011); Figure 2B]. Moreover, DCs (especially
CD8α/CD103+ cDCs and intestinal CD103+CD11b+ cDCs) are
potent producers of bioactive TGF-β [(Annacker et al., 2005;
Coombes et al., 2007; Travis et al., 2007; Yamazaki et al., 2008;
Paidassi et al., 2011); Figure 2B]. Thus, DCs guide the homeosta-
sis of Foxp3+ Tregs via multiple mechanisms.
The importance of DCs for the homeostasis of Foxp3+ Tregs
can be further exemplified by conditions which alter the num-
bers of DCs in vivo. DC-deficient DC mice, CD11c: DTA mice
and DT-treated CD11c-DTR bone marrow chimeras all harbor
decreased numbers of Foxp3+CD25+ Tregs with reduced Foxp3
expression (Darrasse-Jeze et al., 2009; Ohnmacht et al., 2009; Bar-
on et al., 2011a). This extends to humans with DC deficiency
syndromes that are accompanied by reduced numbers of Tregs
(reviewed in Collin et al., 2011). Vice versa, an expansion of the
mouse DC compartment with exogenous FLT3L induces Treg
proliferation (Darrasse-Jeze et al., 2009; Swee et al., 2009).
Are particular DC subsets specialized for the maintenance of
Tregs? Given that all DC subsets express significant amounts of
MHC-class-II in the immature steady-state, Treg activation seems
to be an inherent function of DCs. However, certain DC sub-
sets may more effectively provide additional factors such as IL-2
or active TGF-β. Interestingly, pDCs have been recently shown
to control the homeostasis of intestinal Foxp3+ Tregs (Takagi
et al., 2011). The underlying mechanisms remain to be explored.
Foxp3+ Treg homeostasis is likely enforced by inflammation
which e.g., causes the increased expression of MHC-class-II,
CD80, CD86, and IL-2 (Oldenhove et al., 2003; Yamazaki et al.,
2003; Banerjee et al., 2006; O’Sullivan et al., 2011). In summary,
DCs critically regulate the homeostasis and activation state of
Foxp3+ Tregs.
De novo induction of Foxp3+ Tregs. A second layer of DC/Treg
interaction is based on the finding that conventional T cell
activation by particular DC subsets can lead to the de novo
generation of Foxp3+ Tregs. This specialization is presum-
ably acquired by DC conditioning and depends on the abil-
ity of DCs to produce and/or activate latent TGF-β [(Chen
et al., 2003; Paidassi et al., 2011); Figure 2B]. Moreover, DC-
derived retinoic acid (RA) enhances the TGF-β-mediated gen-
eration of Foxp3+ Tregs [(Hill et al., 2008; Mucida et al.,
2009); Figure 2B]. RA production in DCs is regulated by the
expression of the retinaldehyde-converting enzymes Raldh1 or
Raldh2 (Manicassamy and Pulendran, 2009). GM-CSF, RA and
TLR signaling (especially via TLR2) represent putative Raldh2-
inducing factors within tissues (Manicassamy et al., 2009;
Yokota et al., 2009; Guilliams et al., 2010a; Jaensson-Gyllenback
et al., 2011). Moreover, β-catenin-dependent signals have been
shown to induce TGF-β, Raldh1 and Raldh2 in intestinal DCs
(Manicassamy et al., 2010). Additionally, the uptake of apop-
totic DCs may imprint Foxp3+ Treg-inducing capacity (Kushwah
et al., 2009, 2010). As another example, PD-1 ligation on activated
T cells was implied in DC-mediated Treg induction [(Fukaya
et al., 2010); Figure 2B]. The contribution of these individual
mechanisms for Treg induction and the overall role of induced
Foxp3+ Tregs for tolerance are still under investigation. A recent
study suggests that induced Foxp3+ Tregs make an important
contribution to self tolerance (Haribhai et al., 2011). Moreover,
Rudensky and colleagues reported a role for iTregs in suppress-
ing Th2 inflammation at mucosal surfaces (Josefowicz et al.,
2012).
Which DC subsets are capable of inducing Foxp3+ Tregs?
So far, only mesenteric lymph node CD8α/CD103+ and
CD103+CD11b+ cDCs, splenic CD8α/CD103+ cDCs and sub-
cutaneous lymph node CD11b+ cDCs were described to possess
endogenous Foxp3+ Treg inducing activity (Coombes et al., 2007;
Sun et al., 2007; Yamazaki et al., 2008; Guilliams et al., 2010a;
Azukizawa et al., 2011). Lung CD8α/CD103+ and CD11b+
cDC subsets display Raldh2 activity, but have not been func-
tionally tested yet (Guilliams et al., 2010a). In line with these
findings, migratory lamina propria CD103+CD11b+ cDCs were
shown to mediate oral tolerance and imprint gut homing prop-
erties to T cells including induced Foxp3+ Tregs (Jaensson
et al., 2008; Schulz et al., 2009; Cassani et al., 2011; Hadis
et al., 2011). Furthermore, antigen delivery to CD8α/CD103+
cDCs via DEC-205 or DNGR-1 can induce Foxp3+ Tregs in
the absence of inflammation, yet provokes immunity after co-
administration of adjuvants (Kretschmer et al., 2005; Yamazaki
et al., 2008; Joffre et al., 2010). This functional dichotomy of
CD8α/CD103+ cDCs is consistent with the reported abroga-
tion of Treg-inducing functions upon inflammation (Laffont
et al., 2010; Hackl et al., 2011). However, DC stimulation by
pathogens (e.g., via TLR2) may augment the production of
RA and thereby Treg induction (Manicassamy et al., 2009).
Indeed, certain infections are known to be accompanied by an
expansion of Foxp3+ Tregs (Belkaid, 2007; Berod et al., 2012).
However, it is still controversial whether this involves genuine
de novo induction or expansion of pre-existing Foxp3+ Tregs.
Once induced, Foxp3+ Tregs were shown to expand heavily even
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during immunogenic conditions (Kretschmer et al., 2005). This
may reflect the previously discussed increased homeostasis of
Foxp3+ Tregs by matured vs. steady-state DCs (see “Foxp3+ Treg
maintenance/activation”). Nevertheless, the suppressive activity
of Foxp3+ Tregs can be negatively regulated (e.g., by certain
inflammatory cytokines), possibly to prevent excessive tolerance
(Anz et al., 2010).
One can ask the question why only few DC subsets are
endowed with Foxp3+ Treg-inducing capacity. This may relate to
anatomical localization. For example, mucosal surfaces like the
intestine are heavily challenged with microbes. This may lead to
the constant triggering e.g., of TLR2 and β-catenin-dependent
pathways in intestinal compared to splenic DCs (Manicassamy
et al., 2009, 2010). Alternatively, DC subsets could be differen-
tially sensitive toward imprinting signals. Moreover, the stability
of imprinting could differ between DC subsets. All of these factors
may crystallize toward subset specialization within a dedicated
organ (e.g., tolerogenic CD103+CD11b+ cDCs versus immuno-
genic CD11b+ Mo-DCs in the steady state intestine), yet may
at the same time explain variability between tissues (e.g., intes-
tine versus skin). Markers that distinguish natural from induced
Foxp3+ Tregs would greatly help to clarify the importance of indi-
vidual DC subsets for Treg induction. According to recent studies,
the previously reported candidate Helios seems to be less specific
for natural Tregs than originally thought (Thornton et al., 2010;
Akimova et al., 2011; Gottschalk et al., 2012).
Recessive peripheral tolerance
Recessive tolerance is a T cell intrinsic process. In the absence
of infection, trauma or necrosis, DCs maintain a functionally
immature state and continuously process and present self antigens
(Reis E Sousa, 2006). Although such recognition of self antigen
by T cells can lead to their expansion, they may remain func-
tionally impaired due to clonal anergy (Figure 2C). This process
partially depends on CTLA-4 and PD-1 expression by activated T
cells [(Nishimura et al., 1999; Freeman et al., 2000; Greenwald
et al., 2001; Keir et al., 2006; Fife et al., 2009); Figure 2C and
not depicted]. Antigen presentation by DCs can also result in
activation-induced cell death (Kurts et al., 1997; Adler et al.,
1998; Sakaguchi et al., 2008; Mueller, 2010). This clonal deletion
involves Fas-, Bim- or TNF-dependent apoptosis in responding T
cells [(Hughes et al., 2008; Hutcheson et al., 2008; Weant et al.,
2008; Luckey et al., 2011); Figure 2C]. Apoptotic immune cells
or tissue cells were shown to actively enforce this process, partly
through suppression of NFκB signaling in DCs (Liu et al., 2002;
Rothlin et al., 2007). Notably, steady state DCs can be sufficient to
induce immunity in particular settings (Mayerova et al., 2004). It
has been discussed that the decision between peripheral tolerance
and immunity may be based on only subtle differences that deter-
mine howmany T cells survive an initial wave of clonal expansion
(Reis E Sousa, 2006). The nature of these signals is still a matter
of intensive investigation.
Skin, lung, and splenic, if not all CD8α/CD103+ DCs are
believed to critically maintain CD8+ T cell tolerance by cross-
presenting cell-associated antigens (Del Rio et al., 2007; Qiu
et al., 2009; Henri et al., 2010; Desch et al., 2011). Indeed,
in the absence of co-stimulation, antigen targeting to steady
state CD8α/CD103+ DCs via an antigen-coupled αCD103 anti-
body was recently shown to promote CD8+ T cell tolerance
and protection from allergic airway inflammation (Semmrich
et al., 2012). Similarly, mice harboring cross-presentation defi-
cient DCs accumulate autoreactive CD8+ T cells (Luckashenak
et al., 2008). However, clonal deletion can turn into potent immu-
nity upon DC maturation (Hawiger et al., 2001; Bonifaz et al.,
2002; Semmrich et al., 2012). Similarly, co-stimulation of CD28
via CD80/CD86 antagonises clonal anergy (Harding et al., 1992).
Thus, these mechanisms maintain peripheral tolerance in the
steady state, but seem reversible upon inflammation. This pattern
of regulation seems opposite to the homeostasis of Foxp3+ Tregs.
Negative feedback regulation
DCs can also enforce tolerance by initiating negative regulatory
feedback loops. Foxp3+ Tregs represent one prominent exam-
ple (Figure 2D). Once activated by DCs, Foxp3+ Tregs suppress
the production of FLT3L by still incompletely characterized cell
populations, resulting in the strictly regulated development of
new DCs from their precursors (Kim et al., 2007; Liu et al.,
2009; Schildknecht et al., 2010). In the steady state, the cellu-
lar sources for FLT3L were recently described to be widespread,
including hematopoietic and non-hematopoietic cells, yet their
relative contribution to DC development can vary between dif-
ferent tissues (Miloud et al., 2012). In addition to restricting DC
numbers, Foxp3+ Tregs negatively regulate DC function. This can
be achieved by simply outcompeting naïve T cells for interaction
(Figure 2B). Furthermore, the binding of CTLA-4 to CD80/CD86
leads to the suppression of DC maturation [(Onishi et al., 2008);
Figure 2D]. Accordingly, the relief from Treg-mediated suppres-
sion can cause the maturation of DCs (Schildknecht et al., 2010).
By suppressing DC maturation, Foxp3+ Tregs in turn promote
recessive peripheral tolerance (see “Recessive peripheral toler-
ance”). Another consequence of the CTLA-4-CD80/86 interac-
tion is the release of indolamine-2,3-dioxygenase (IDO) which
converts tryptophan into toxic metabolites (Figure 2D). These
induce the apoptosis of conventional T cells (Grohmann et al.,
2002). Additionally, IDO enforces the suppressive function of
Foxp3+ Tregs (Sharma et al., 2009). Notably, the disruption of
CTLA-4 signals can abrogate the suppressive function of Tregs
in vivo (Sakaguchi et al., 2008; Wing et al., 2008). This under-
lines the importance of CTLA-4-mediated feedback inhibition for
the suppressive activity of Foxp3+ Tregs. Foxp3+ Tregs can also
secrete TGF-β which results in the de novo generation of Foxp3+
Tregs and in the suppression of DC functions (Figures 2B andD).
TGF-β can be additionally provided by activated T cells or by DCs
themselves (Coombes et al., 2007; Rubtsov and Rudensky, 2007;
Travis et al., 2007).
The important question remains whether Foxp3+ Tregs pref-
erentially engage such regulatory loops in particular DC subsets.
Given that FLT3L is a universal growth factor for most DCs and
their progenitors, Foxp3+ Tregs probably globally control DC
homeostasis (Merad et al., 2008; Kingston et al., 2009). Similarly,
the targets of CTLA-4 (CD80/CD86) are expressed by most DC
subsets. However, it cannot be excluded that Tregs are more
potent inhibitors of particular DC subsets by still undefined
mechanisms. Interestingly, Treg-dependent DC inhibition does
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not affect MHC-class-II expression, possibly in order to preserve
Foxp3+ Treg homeostasis as discussed above (Onishi et al., 2008;
Darrasse-Jeze et al., 2009).
IL-10 represents another example for feedback regulation.
This cytokine inhibits DCmaturation and function. Additionally,
IL-10 induces IL-10-producing Foxp3− TR1 cells (Figure 2D),
thus amplifying negative regulation by so-called infectious tol-
erance (O’Garra and Vieira, 2007; Barnes and Powrie, 2009).
DCs produce IL-10 upon activation e.g., through DC-SIGN-,
TLR2- or Wnt/β-catenin-dependent signaling pathways [(Dillon
et al., 2006; Manicassamy et al., 2010; Hajishengallis and Lambris,
2011); Figure 2D]. This may especially protect tissues from
immune pathology that are continuously challenged with micro-
bial ligands triggering these receptors. This is supported by
IL-10-deficient mice which spontaneously suffer from severe
colitis (Kuhn et al., 1993). In conclusion, DCs make use of
several mechanisms to induce negative regulatory loops which
reinforce tolerance. While some of these mechanisms might
prevail in the steady state, other loops may primarily serve
to counter-regulate inflammation at specific anatomical loca-
tions.
ANTIGEN PRESENTATION
DCs acquire exogenous antigens by diverse mechanisms. These
include the ingestion of particles (phagocytosis), the engulfment
of extracellular fluid (macropinocytosis), and receptor-mediated
endocytosis. Exogenous antigens typically gain access to the
MHC-class-II presentation pathway. However, these can also be
shuttled to the MHC-class-I pathway, a process referred to as
cross-presentation (reviewed in Kurts et al., 2010). In contrast,
endogenous antigens are classically presented on MHC-class-I
molecules.
Since most of the so far dissected mechanisms of tolerance
involve antigen recognition, the mode of antigen presentation to
T cells also needs to be considered as a component of tolerance.
Major insights into such details have been gained by the possibil-
ity to target antigens to particular DC subsets in situ via the use
of antibody conjugates (reviewed in Caminschi and Shortman,
2012). For example, antigen targeting to splenic CD11b+ cDCs
(via 33D1) or to CD8α/CD103+ cDCs (via DEC205) revealed
DC-intrinsic specializations for distinct MHC presentation path-
ways. CD11b+ cDCs efficiently form MHC-class-II: peptide
complexes whereas CD8α/CD103+ cDCs potently cross-present
peptides on MHC-class-I molecules (Dudziak et al., 2007). In
contrast, steady-state pDCs express low levels of MHC-class-
II (Wu and Shortman, 2005). Consequently, CD11b+ cDCs
may be more efficient at activating existing CD4+Foxp3+ Tregs
compared to CD8α/CD103+ cDCs and pDCs, especially when
the antigen is limited. In contrast, CD8α/CD103+ cDCs effi-
ciently generate active TGF-β, and suboptimal antigen recogni-
tion enhances the de novo generation of Foxp3+ Tregs (Yamazaki
et al., 2008). Thus, differences in the antigen uptake capacity
and/or expression of the antigen presentation machinery can
result in specializations for certain tolerance mechanisms.
The type of uptake receptor triggered on a particular DC can
further modulate the resulting immune response. This can be
exemplified by the human C-type lectin DC-specific intercellular
adhesion molecule-3 grabbing non-integrin (DC-SIGN). This
endocytic receptor capable of signaling via Raf-1 is expressed
predominantly on human cDCs, yet lacks functionally related
homologues in mice. DC-SIGN binds both self antigens and var-
ious pathogens including mycobacteria. Mice expressing human
DC-SIGN on CD11c+ DCs were shown to have reduced
immunopathology during mycobacterial infection when com-
pared to wildtype mice (Schaefer et al., 2008). Accordingly,
human DC-SIGN+ DCs from these infected mice produced sig-
nificantly less IL-12p40 than wildtype DCs. Additionally, the
targeting of DC-SIGN via an antigen-coupled antibody enhances
cross-presentation about 1000-fold when compared to unspecific
antigen uptake (Tacken et al., 2011). These examples illustrate
that the mode of antigen uptake can strongly influence the
resulting immune response.
Another important factor is the kinetics of antigen presenta-
tion. It has been suggested that persistent antigen presentation
may rescue T cells from deletion after their initial priming (Reis E
Sousa, 2006). Indeed, antigen targeting to DNGR-1 was shown
to induce potent CD4+ T cell-dependent antibody responses
as a result of persistent antigen presentation (Caminschi and
Shortman, 2012). In contrast, poor antibody responses are seen
when targeting DEC205 or Clec12A, although all three recep-
tors are expressed by CD8α/CD103+ cDCs (Lahoud et al., 2011).
Other parameters that can regulate the kinetics of antigen presen-
tation may include the half-life of MHC: peptide complexes on
the DC surface, the half-life of DCs themselves and the migra-
tion of peripheral DCs into secondary lymphoid organs. Notably,
inefficient antigen presentation can result in ignorance as a pas-
sive type of tolerance (Mueller, 2010). Thus, the mode, efficiency
and kinetics of antigen presentation are important components
of tolerance.
DCs AND AUTOIMMUNITY
We have depicted how DCs control multiple layers of tolerance
(section “Layers of DC-mediated tolerance”). Consequently, it
could be expected that the disruption of DC-mediated tolerance
layers or the elimination of DCs that execute such programmes
lead to the breakdown of self tolerance. This complex issue can
only be briefly discussed (also from a technical point of view) in
this section and is summarized in Figure 3.
DISRUPTION OF TOLERANCE LAYERS
Foxp3+ Tregs are an important component of DC-dependent tol-
erance (Figure 2). Indeed, loss-of-function mutations of Foxp3 in
mice and men, or the ablation of Foxp3+ cells in transgenic mice,
all lead to lethal autoimmunity (Brunkow et al., 2001; Gambineri
et al., 2003; Kim et al., 2007; Lahl et al., 2007; Sakaguchi et al.,
2008). Due to the disrupted negative feedback loop between
Foxp3+ Tregs and DCs, FLT3L accumulates and DCs expand
in Foxp3+ Treg-deficient mice [(Liu et al., 2009); Figure 3C].
Additionally, DCs mature (see “Negative feedback regulation”)
and prime autoreactive T cells (Figure 3C). Notably, these include
tumor-specific T cells (Klages et al., 2010). Moreover, Foxp3+
Tregs increase the threshold for foreign-specific immunity which
may occur both at the priming and effector phase (Baru et al.,
2010; Haque et al., 2010; Suttner et al., 2010; Arnold et al., 2011;
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FIGURE 3 | DCs in the suppression of autoimmunity. The role of DCs in
the suppression of autoimmunity is complex and a matter of discussion.
(A) In the steady state, DCs are believed to contribute to the negative
selection of autoreactive T cells. Few autoreactive T cell clones that escape
negative selection can be efficiently controlled by Foxp3+ Tregs in the
periphery, a process that critically depends on the continuous activation and
homeostasis of Tregs by DCs. Equilibrium between the production of the
myeloid growth factor FLT3L and its consumption maintains a constant
number of DCs and other myeloid cells. (B) DC-deficient (DC) mice
may exhibit defective negative selection, resulting in the increased seeding of
the periphery with self-reactive T cells. Additionally, the absence of peripheral
DCs impairs Foxp3+ Treg homeostasis and activation, resulting in a
substantial reduction of Treg numbers and probably also functionality. The
massive accumulation of FLT3L due to the absence of DCs as
key consumers of this growth factor leads to a myeloproliferative syndrome.
Signs of increased autoreactivity are detectable in DC mice, yet the
absence of DCs most likely prevents the activation of self-reactive
T cells and thus the full precipitation of systemic autoimmunity. (C) The
absence of functional Foxp3+ Tregs (Tregs; e.g., in scurfy mice) is
compatible with a normal negative selection, yet provokes severe
systemic autoimmunity due to the defective negative regulation of
DCs and autoreactive T cells. An increased level of FLT3L in the
absence of Foxp3+ Tregs expands the numbers of DCs and other myeloid
cells.
Blankenhaus et al., 2011; Dietze et al., 2011; Hadis et al., 2011;
Navarro et al., 2011).
TGF-β is another key molecule in tolerance. This cytokine
has important immunoregulatory functions, e.g., the mainte-
nance of Foxp3+ Tregs and the suppression of DC functions
(Figure 2). A failure of DCs to activate latent TGF-β through
the αvβ8 integrin results in autoimmunity and colitis (Travis
et al., 2007). Moreover, the disruption of TGF-β signaling specif-
ically in DCs renders mice susceptible to experimental autoim-
mune encephalomyelitis (Laouar et al., 2008). Similarly, the
DC-intrinsic disruption of other global inhibitory proteins (e.g.,
Blimp-1, A20) or the artificial engagement of stimulatory path-
ways (e.g., Tim-1, CD70) can precipitate immune dysregulation
(Keller et al., 2008; Kim et al., 2011; Kool et al., 2011; Xiao
et al., 2011). Thus, interfering with DC-mediated tolerancemech-
anisms can clearly induce autoimmunity (Figure 3C).
DC ABLATION
Various mouse models with constitutive DC deficiency are avail-
able. Mice deficient in certain transcription factors involved in
DC differentiation (like RelB, E2-2 or Batf3) lack specific DC
populations, whereas other mutant mice lack several DC sub-
sets (Belz and Nutt, 2012). For example, mice that lack FLT3L,
an essential growth factor for DC progenitors, cDCs and pDCs,
have severely reduced numbers of DCs (Kingston et al., 2009).
Although these models have helped to unveil several aspects
of DC development, they often have the main drawback that
the transcription factors or growth factors deleted are not DC
specific and might therefore affect other immune cell popula-
tions. In the last years, two mouse models have been devel-
oped in which the suicide gene diphtheria toxin A is expressed
in CD11c+ cells (DC mice, CD11c: DTA mice). This leads
to the constitutive ablation of DCs (Birnberg et al., 2008;
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Ohnmacht et al., 2009). Moreover, CD11c-DTR mice allow for
the inducible depletion of DCs by administration of diphtheria
toxin (Jung et al., 2002). By using these mouse models, a role
for DCs in the maintenance of tolerance has been suggested.
Indeed, increased proportions of Th1 and Th17 cells, hyper-
gammaglobulinemia and/or autoantibody formation have been
independently detected in DC-, CD11c:DTA-, FLT3L−/−- and
inducible DC-depleted mice (Birnberg et al., 2008; Darrasse-Jeze
et al., 2009; Ohnmacht et al., 2009). In support of these findings,
DCmice exhibit defective negative selection [(Ohnmacht et al.,
2009); Figure 3B]. Furthermore, humans with DC, monocyte, B
and NK lymphoid (DCML) deficiency can develop autoimmu-
nity (Collin et al., 2011). Altogether, these studies suggest that
DC deficiency can result in increased autoreactivity (Figure 3B).
However, both DC and CD11c:DTA mice develop a myelopro-
liferative syndrome that has been explained by the accumulation
of FTL3L due to the absence of cDCs (Figure 3B). For this reason,
the observed abnormalities of adaptive immune cells have been
attributed to the myeloproliferative disease rather than to a pri-
mary autoimmune disorder (Birnberg et al., 2008; Bar-on et al.,
2011a).
The connection between myeloproliferative disease (as a con-
sequence of DC ablation) and autoimmunity is an intriguing
question. FLT3L−/− mice resistant to FLT3L-dependent myelo-
proliferative disease display features of increased autoreactivity
similar toDC andCD11c:DTAmice (Darrasse-Jeze et al., 2009).
This extends to humans with DCML deficiency who can develop
autoimmune manifestations in the absence of myeloprolifera-
tion (Collin et al., 2011). Based on these data, one can argue
that increased autoreactivity is not necessarily a consequence of
myeloproliferation. Furthermore, the transfer of CD4+CD25+
Tregs can prevent autoreactivity in DT-treated CD11c-DTR
chimeras (Darrasse-Jeze et al., 2009). Foxp3+ Treg dysfunction
may even contribute to myeloproliferation given that Foxp3+
Tregs suppress FLT3L production (Liu et al., 2009). Bar-On
et al. use the lack of autoreactivity in CD80/86−/− :CD11c:DTA
mixed bone marrow chimeras as a supportive argument (Bar-on
et al., 2011a). However, one could envisage that CD80/CD86-
deficient DCs may sufficiently provide MHC-class-II-dependent
signals to Foxp3+ Tregs and stimulate their suppressive func-
tions (Sakaguchi et al., 2008; Darrasse-Jeze et al., 2009). Thus,
CD80/86−/− DCs may inhibit autoreactivity when compared to
DC-deficient settings in which Foxp3+ Tregs experience virtually
no antigenic stimulation. This does not necessarily conflict with
reduced Foxp3+ Treg numbers in both scenarios.
More recently, mouse models that allow the depletion of
specific DC subsets have been generated to examine the role
of particular DC subsets in tolerance and immunity. Langerin
(CD207)-positive LCs are located in the epidermis and are
believed to take up and transport self antigens to the skin-
draining lymph nodes (Waithman et al., 2007). Both inducible
(Langerin-DTR) and constitutive (Langerin-DTA) LC depletion
models have been developed. However, no obvious onset of
skin-specific or systemic autoimmunity has been reported in
these LC-ablated mice (Bennett et al., 2005; Kaplan et al., 2005;
Kissenpfennig et al., 2005). This is also not the case when the
skin of LC-deficient mice is infected with Leishmania major,
suggesting that Langerhans cells do not play a major role in
suppressing autoimmunity (Kautz-Neu et al., 2011).
Similarly, the contribution of CD8α/CD103+ DCs to tol-
erance has been examined. Although CD103 is not a univer-
sal marker for Foxp3+ Treg-inducing DCs (Azukizawa et al.,
2011), CD8α/CD103+ and CD103+CD11b+ cDCs have promi-
nent steady-state regulatory functions across tissues (Bonifaz
et al., 2002; Coombes et al., 2007; Henri et al., 2010). Yet,
Batf3−/− mice which constitutively lack CD8α/CD103+ DCs,
have a normal steady state phenotype (Edelson et al., 2010).
Autoimmunity is also not induced upon infections in these
mice. In fact, the absence of CD8α/CD103+ cDCs results in
defective immunity e.g., against influenza, poxvirus, salmonella
and West Nile Virus (Hildner et al., 2008; Bogunovic et al.,
2009; Beauchamp et al., 2010; Ho et al., 2011). In this case
it is thus likely that other DC subsets can compensate for the
loss of CD8α/CD103+ cDCs to maintain tolerance. Additionally,
mice that lack intestinal CD103+CD11b+ cDCs do not sponta-
neously develop colitis or autoimmunity. However, severe colitis
is induced in these mice upon challenge with dextrane sodium
sulphate (Varol et al., 2009). Conversely, an increase in the pro-
portion of CD103+CD11b+ cDCs by FLT3L treatment results
in an increase of Foxp3+ Tregs and amelioration of TNF-driven
ileitis (Collins et al., 2011). Thus, CD103+CD11b+ cDCs may
balance intestinal immunity in specific situations, but seem to
lack a unique tolerogenic function.
Finally, pDCs need to be mentioned. Although pDCs are
implied in the pathogenesis of autoimmune diseases like systemic
lupus erythematosus, they have also been suggested to promote
self tolerance via negative selection and Foxp3+ Treg homeosta-
sis (Tian et al., 2007; Matta et al., 2010; Hadeiba et al., 2012).
BDCA2-DTR and SiglecH-DTRmice have recently become avail-
able to selectively deplete pDCs. Following DT administration,
these mice were so far not reported to develop autoreactivity, even
after infection with murine cytomegalovirus or vesicular stomati-
tis virus (Swiecki et al., 2010; Takagi et al., 2011). Whether this is
a matter of depletion efficiency and kinetics, or points towards
a dispensable role of pDCs in maintaining tolerance, remains
to be resolved (also discussed in “Technical aspects of DC abla-
tion”). In conclusion, although there is definite evidence that
DCs substantially contribute to prevent autoimmunity by act-
ing at different layers of tolerance (Figure 2; section “Disruption
of tolerance layers”), no DC subset has been identified till date
which is required to maintain self tolerance in a non-redundant
fashion. Constitutive pDC-deficient mice and mice that specif-
ically eliminate CD11b+ cDCs remain to be developed in this
regard. Moreover, recent studies suggest that certain technical and
conceptual aspects need to be considered to resolve these findings.
TECHNICAL ASPECTS OF DC ABLATION
Depletion efficiency and side effects
The DC depletion efficiency as well as secondary effects induced
by DC depletion can influence the outcome of experiments and
their interpretation. One example is represented by DC and
CD11c: DTA mice both of which re-activate DTA expression in
CD11c+ DCs. DCmice lack cDCs, pDCs, and LCs and develop
autoimmunity (Ohnmacht et al., 2009). In contrast, CD11c: DTA
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mice possess pDCs and LCs, but lack cDCs and autoimmunity
(Birnberg et al., 2008). This could point toward a critical role of
pDCs and LCs in tolerance induction. However, as mentioned,
constitutive LC-deficient mice do not develop autoimmunity
(Kaplan et al., 2005). Transgenic mice with a constitutive and
selective deficiency in pDCs would be very useful to address this
still open question. The differential depletion of CD11c+ DC
subsets in DC and CD11c: DTA mice is likely attributed to
different DTA expression levels. Since the same BAC-transgenic
CD11c-Cre line was utilized in both cases, these differences could
relate to the two different DTA strains used (Birnberg et al., 2008;
Ohnmacht et al., 2009).
Furthermore, side effects induced by the ablation of DCs can
be problematic. It was recently shown that CD11c-DTR and
CD11c-DOG mice develop neutrophilia 6–24 h after DC deple-
tion by injection of DT (Tittel et al., 2012). This is mechanistically
distinct from myeloproliferation and is guided by CXCL1/2-
dependent recruitment of neutrophils from the bone marrow.
According to the timing of DC depletion, this can result in oppos-
ing phenotypes in a pyelonephritis model using uropathogenic
Escherichia coli (Tittel et al., 2012). The reason underlying this
early neutrophila is still unclear. One could speculate that the
massive apoptosis induced by DT can have side effects on the
immune system. Additionally, DT can itself have non-specific
toxic effects in wildtype mice, especially when combined with
protocols causing activation of the immune system (Meyer Zu
Horste et al., 2010). Different DT batches can vary substan-
tially in their toxicity, underlining the requirement for careful
titration (Lahl and Sparwasser, 2011). Nevertheless, early neu-
trophila is not observed when treating wildtype mice with DT
or when using CD11c-LuciDTR mice for DC depletion (Tittel
et al., 2012). The basis for these findings requires further eluci-
dation.
Additionally, it has been recently shown that DCs interact
with high endothelial venules and thereby guide the entry of
naïve T cells into lymph nodes (Moussion and Girard, 2011).
Consequently, the depletion of DCs may have previously unap-
preciated side effects on T cell responses by altering the lymph
node structure. Whether this relies on particular DC subsets has
to be investigated. Taken together, both the depletion efficiency
and side effects associated with DC depletion may influence the
interpretation of data.
Specificity
The promoters and transgene targeting strategies used to drive
the ablation of DCs or DC subsets can also strongly influence
the outcome of experiments. One classical example is LCs. Three
independent models allowing for the inducible or constitutive
depletion of LCs based on the C-type lectin Langerin (CD207)
generated apparently contradictory results (reviewed in Kaplan
et al., 2008). Using Langerin-IRES-DTR-eGFP knock-in mice,
no role of LCs for contact hypersensitivity (CHS) reactions was
noted (Kissenpfennig et al., 2005). However, Langerin-DTR-eGFP
knock-in mice revealed a contribution of LCs to CHS reactions
using a similar experimental protocol (Bennett et al., 2005).
In contrast, BAC-transgenic Langerin-DTA mice with constitu-
tive LC deficiency develop enhanced CHS responses suggesting
a regulatory role of LCs (Kaplan et al., 2005). One important
factor contributing to these diverse findings is the specificity of
Langerin expression. Langerin is not only expressed by LCs, but
also at lower levels by CD8α/CD103+ cDCs, as well as on a sub-
set of CD103−CD11blow dermal DCs (Kaplan et al., 2008; Henri
et al., 2010). Thus, the differential depletion of other Langerin+
DC subsets may explain the different outcomes of the CHS reac-
tions. Indeed, only Langerin-DTA mice specifically target LCs.
This was explained by the differential regulation of the human
langerin gene locus that was used to generate Langerin-DTAmice
(Kaplan et al., 2008). Therefore, although depletion models have
proven to be useful to answer several questions, these models still
have limitations and the specificity of cell ablation in a partic-
ular model needs to be considered. Of course, also additional
factors such as the depletion- and repopulation kinetics, tran-
sient versus permanent depletion approaches and the microbial
environment can have a strong impact on experiments assess-
ing DC functions and autoimmunity. The same applies to both
the antigen dose or the administration route used for immuniza-
tions. These factors can for example determine whether addi-
tional and anatomically distant DC populations have access to
antigen.
SUMMARY AND PROPOSEDMODEL
In summary, components of the maturation model (Figure 1A),
the functional dichotomy model (Figure 1B) and the subset spe-
cialization model (Figure 1C) can be combined to describe DC-
mediated tolerance. The strict adherence to only one model can
explain paradoxical experimental findings like the abrogation of
particular tolerance programs during inflammation (outlined in
section “Tolerogenic DCs”). At present, we favor the idea that
multiple layers of tolerance (Figure 2) are distributed among one
or multiple DC subsets. Therefore, any DC can formally be con-
sidered “tolerogenic” by executing at least one layer of tolerance.
The different layers of tolerance influence each other and can
be differentially regulated in order to allow powerful immune
responses against pathogens while at the same time restraining
autoimmunity.
In the steady state, recessive peripheral tolerance (anergy, dele-
tion) is a default programme of DC-mediated tolerance, given
that antigen and antigen-specific T cells are available. On the con-
trary, only few specialized DCs are capable of de novo generation
of Foxp3+ Tregs, whereas homeostasis and activation of existing
Foxp3+ Tregs is a global function of DCs. Foxp3+ Tregs negatively
control both DC numbers and maturation and thereby enforce
steady-state tolerance. Inflammatory signals cause functional
DC maturation that antagonises recessive peripheral tolerance.
Similarly, Treg-inducing properties can be abrogated, whereas
the activation and homeostasis of existing Foxp3+ Tregs con-
tinue or are even enforced. Foxp3+ Tregs disrupt DC activity and
thereby counter-regulate immunity at different levels. Additional
mechanisms of feedback regulation can be promoted, e.g., via
production of IL-10. As DCs continue to execute tolerogenic
programmes during inflammation, tolerance and immunity may
represent parallel events tentatively executed by the same DC. Yet
certain subsets can be specialized in particular layers of tolerance
and some layers may be more resistant toward inflammatory
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signals than others. This, in the sum, allows the initiation of
immunity, whereas at the same time self tolerance is actively
maintained.
Past research using DC depletion models has provided impor-
tant insights into DC-mediated tolerance, yet the ablation of DC
subsets so far failed to induce autoimmunity. If one excludes
technical aspects as an explanation, one could postulate that
a non-redundant tolerogenic DC subset simply doesn’t exist.
Moreover, it should be considered that DCs are required to
induce (auto)immunity. Thus, the global breakdown of steady-
state tolerance can be largely masked in the absence of DCs
(Figure 3). This would explain why fatal autoimmunity occurs
when disrupting non-redundant layers of tolerance (such as
Foxp3+ Tregs) while DCs remain present (Figure 3C). Unraveling
the complex mechanisms of DC- and Foxp3+ Treg-mediated
immune regulation across all layers might be the key to the selec-
tive therapeutic manipulation of the immune system. This could
allow for the enhancement of immunity against pathogens and
tumors while suppressing unwanted self-specific responses, and
vice versa.
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